Shares of Bio Green Med Solution (BGMS) surged 14.9% to $1.00 on September 14, after the company's amended registration filing advanced its proposed all-stock acquisition of Future NRG, a Malaysian medical waste-to-energy developer. The deal, valued at $2 billion, is structured as a reverse merger through a Nasdaq-listed micro-cap worth roughly $5 million — a mismatch so extreme it raises fundamental questions about who actually benefits.

  • Current Shareholders Will Own Almost Nothing After the Deal Closes. Based on the $2.0 billion valuation and exchange structure, current BGMS stockholders who collectively owned 100% pre-transaction are expected to own less than 1% of BGMS after closing, with Future NRG's selling shareholders owning over 99% of the common stock. In plain terms, for every dollar of post-merger value, existing holders would get less than a penny's worth of ownership. The number of new shares issued is calculated by dividing the $2.0 billion price tag by the average trading price of BGMS stock in the 30 days before closing — meaning further stock declines before closing would trigger even more share issuance.

  • A $2 Billion Valuation Rests on Thin Revenue and Big International Promises. Future NRG reported 2025 revenue of just $854,337. A fairness opinion valued Future NRG's equity between $1.76 billion and $2.08 billion using a model that assumes rapid expansion into Vietnam, Thailand, and the Philippines. That is a revenue multiple exceeding 2,000x — defensible only if the expansion plan executes flawlessly.

  • BGMS Itself Faces Going-Concern Doubts. Management states that existing cash of $3.5 million as of December 31, 2025, is expected to fund operations only into the third quarter of 2026, and substantial doubt exists about BGMS's ability to continue as a going concern.

Trailing twelve-month revenue was just $747,000, with a net loss of $3.0 million. This is a company that needs a deal to survive.

  • The Rally Follows a Familiar Micro-Cap Playbook. The deal structure implies extreme dilution for current shareholders, but micro-cap traders often bid these "reverse merger" setups higher on the prospect of a new growth narrative and increased liquidity.

BGMS is also seeking authority to raise up to $50 million over 24 months via new stock and warrants — additional dilution waiting in the wings. The deal's outside termination date is December 31, 2026 , leaving a narrow runway to secure shareholder and Nasdaq approval.